Announcements Trials

Browse Landscape

Phase

Phase NA 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 145 Breast Neoplasms 113 Prostatic Neoplasms 58 Multiple Myeloma 57 Neoplasms 54 Lung Neoplasms 46 Neoplasm Metastasis 42 Ovarian Neoplasms 36 Parkinson Disease 4, Autosomal Dominant Lewy Body 34 Leukemia, Lymphocytic, Chronic, B-Cell 33 Colorectal Neoplasms 32 Carcinoma, Renal Cell 26 Recurrence 25 Leukemia, Myeloid, Acute 25 Urinary Bladder Neoplasms 23 Myasthenia Gravis 23 Carcinoma, Hepatocellular 23 Triple Negative Breast Neoplasms 21 Lymphoma, Large B-Cell, Diffuse 21 Squamous Cell Carcinoma of Head and Neck 20 Small Cell Lung Carcinoma 20 Lymphoma, Follicular 18 Fallopian Tube Neoplasms 18 Endometrial Neoplasms 18 Stomach Neoplasms 17 Nasopharyngeal Carcinoma 17 Melanoma 17 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Pancreatic Neoplasms 15 Non-Muscle Invasive Bladder Neoplasms 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Polyps × 90 days × Clear all

NCT06950385 2026-05-22

SERENTA

Rapamycin Holdings Inc.

Phase 3 Recruiting

Gastrointestinal

Adenomatous Polyposis Coli, Polyps

Data powered by HemOnc (CC BY 4.0) Colophon ⚡